की कीमत क्या है Aardvark Therapeutics, Inc. Common Stock (AARD)

का मूल्य Aardvark Therapeutics, Inc. Common Stock (AARD) है $7.22

का बाजार पूंजीकरण क्या है Aardvark Therapeutics, Inc. Common Stock (AARD)

का बाजार पूंजीकरण Aardvark Therapeutics, Inc. Common Stock (AARD) है $158.03M

Aardvark Therapeutics, Inc. Common Stock (AARD) P/B अनुपात

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

वर्ष	P/B अनुपात	परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

वर्ष

P/B अनुपात

परिवर्तन

प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।

कंपनी	P/B अनुपात	P/B अनुपात में अंतर	देश
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

कंपनी

P/B अनुपात

P/B अनुपात में अंतर

देश